Acorda Therapeutics Stock Today
| ACOR Stock | USD 0.66 0.12 15.38% |
Performance0 of 100
| Odds Of DistressOver 87
|
Acorda Therapeutics is selling at 0.66 as of the 19th of April 2024; that is -15.38 percent down since the beginning of the trading day. The stock's lowest day price was 0.61. Acorda Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Acorda Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of February 2006 | Category Healthcare | Classification Health Care |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Acorda Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 1.24 M outstanding shares of which 8.1 K shares are presently shorted by private and institutional investors with about 1.84 trading days to cover. More on Acorda Therapeutics
Moving together with Acorda Stock
| 0.81 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.65 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
Moving against Acorda Stock
| 0.59 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Acorda Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Acorda Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acorda Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Ron Cohen | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Acorda Therapeutics report their recommendations after researching Acorda Therapeutics' financial statements, talking to executives and customers, or listening in on Acorda Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Acorda Therapeutics. The Acorda consensus assessment is calculated by taking the average forecast from all of the analysts covering Acorda Therapeutics. | |||||
Acorda Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Acorda Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Acorda Therapeutics' financial leverage. It provides some insight into what part of Acorda Therapeutics' total assets is financed by creditors.
| |||||
Acorda Therapeutics (ACOR) is traded on NASDAQ Exchange in USA and employs 102 people. Acorda Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 821.03 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acorda Therapeutics's market, we take the total number of its shares issued and multiply it by Acorda Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Acorda Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.24 M outstanding shares of which 8.1 K shares are presently shorted by private and institutional investors with about 1.84 trading days to cover.
Acorda Therapeutics currently holds about 20.7 M in cash with (13.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Acorda Therapeutics Probability Of Bankruptcy
Ownership AllocationAlmost 86.0 percent of Acorda Therapeutics outstanding shares are held by general public with 0.689 (percent) owned by insiders and only 13.22 % by other corporate entities.
Check Acorda Ownership Details
Acorda Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Acorda Therapeutics jumping above the current price in 90 days from now is close to 99%. The Acorda Therapeutics probability density function shows the probability of Acorda Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.9455. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Acorda Therapeutics will likely underperform. Additionally, acorda Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Acorda Therapeutics to move above the current price in 90 days from now is close to 99 (This Acorda Therapeutics probability density function shows the probability of Acorda Stock to fall within a particular range of prices over 90 days) .
Acorda Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Acorda Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acorda Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acorda Therapeutics' value.| Instituion | Recorded On | Shares | |
| First Manhattan Co. Llc | 2023-12-31 | 3.0 | |
| Qube Research & Technologies | 2023-12-31 | 1.0 | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 1.0 | |
| Tower Research Capital Llc | 2023-12-31 | 0.0 | |
| Fmr Inc | 2023-09-30 | 0.0 | |
| Deutsche Bank Ag | 2023-12-31 | 0.0 | |
| Group One Trading, Lp | 2023-09-30 | 0.0 | |
| Davidson Kempner Capital Management Lp | 2023-12-31 | 55.1 K | |
| Renaissance Technologies Corp | 2023-12-31 | 45.8 K | |
| Acadian Asset Management Llc | 2023-12-31 | 33.7 K | |
| Vanguard Group Inc | 2023-12-31 | 10.8 K |
Acorda Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Acorda Therapeutics market risk premium is the additional return an investor will receive from holding Acorda Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acorda Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Acorda Therapeutics' alpha and beta are two of the key measurements used to evaluate Acorda Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.23 | |||
| Standard Deviation | 12.02 | |||
| Variance | 144.4 | |||
| Risk Adjusted Performance | (0.15) |
Acorda Stock Against Markets
Picking the right benchmark for Acorda Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Acorda Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Acorda Therapeutics is critical whether you are bullish or bearish towards Acorda Therapeutics at a given time. Please also check how Acorda Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Acorda Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Acorda Therapeutics Corporate Directors
Acorda Therapeutics corporate directors refer to members of an Acorda Therapeutics board of directors. The board of directors generally takes responsibility for the Acorda Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Acorda Therapeutics' board members must vote for the resolution. The Acorda Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Lorin Randall | Independent Director | Profile | |
| John Kelley | Independent Director | Profile | |
| Peder Jensen | Independent Director | Profile | |
| Ian Smith | Independent Director | Profile |
How to buy Acorda Stock?
Before investing in Acorda Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Acorda Therapeutics. To buy Acorda Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Acorda Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Acorda Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Acorda Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Acorda Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Acorda Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Acorda Therapeutics?
The danger of trading Acorda Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acorda Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acorda Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acorda Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acorda Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Acorda Stock analysis
When running Acorda Therapeutics' price analysis, check to measure Acorda Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acorda Therapeutics is operating at the current time. Most of Acorda Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acorda Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acorda Therapeutics' price. Additionally, you may evaluate how the addition of Acorda Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Acorda Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acorda Therapeutics. If investors know Acorda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acorda Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.873 | Earnings Share (203.57) | Revenue Per Share 94.713 | Quarterly Revenue Growth 0.207 | Return On Assets (0.06) |
The market value of Acorda Therapeutics is measured differently than its book value, which is the value of Acorda that is recorded on the company's balance sheet. Investors also form their own opinion of Acorda Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acorda Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acorda Therapeutics' market value can be influenced by many factors that don't directly affect Acorda Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acorda Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acorda Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acorda Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.